Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FGF R2 (IIIc)

FGF R2 (IIIc)

Brief Information

Name:Fibroblast growth factor receptor 2
Target Synonym:BEK,K-sam,KGFR,FGFR2,Fibroblast Growth Factor Receptor 2,Keratinocyte Growth Factor Receptor,Bacteria-Expressed Kinase,Protein Tyrosine Kinase, Receptor Like 14,BEK Fibroblast Growth Factor Receptor,Craniofacial Dysostosis 1,Jackson-Weiss Syndrome,Pfeiffer Syndrome,Crouzon Syndrome,CD332 Antigen,FGFR-2,BFR-1,CD332,BBDS,CEK3,ECT1,TK14,TK25,CFD1,KSAM,JWS,EC:2.7.10.1,EC 2.7.10.1,Receptor, Fibroblast Growth Factor, Type 2,EC 2.7.10
Number of Launched Drugs:7
Number of Drugs in Clinical Trials:20
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
FGC-H5225 Human Human FGF R2 (IIIc) protein, His Tag (MALS verified)
FGC-H5225-structure
FGC-H5225-sds
FGC-H5225-elisa_1

Part of Bioactivity data

FGC-H5225-MALS-HPLC
Human FGFR2 (IIIc), His Tag (Cat. No. ) MALS images

The purity of Human FGFR2 (IIIc), His Tag (Cat. No. FGC-H5225) is more than 90% and the molecular weight of this protein is around 45-55 kDa verified by SEC-MALS.

Bioactivity-ELISA
Human FGFR2 (IIIc), His TagHuman FGFR2 (IIIc), His Tag (Cat. No. FGC-H5225) ELISA bioactivity

Immobilized Human FGFR2 (IIIc), His Tag (Cat. No. FGC-H5225) at 5 μg/mL (100 μL/well) can bind Biotinylated Human FGF basic, Tag Free with a linear range of 0.04-1.25 μg/mL (Routinely tested).

FGC-H5225-ELISA
Human FGFR2 (IIIc), His TagHuman FGFR2 (IIIc), His Tag (Cat. No. FGC-H5225) ELISA bioactivity

Immobilized Human FGFR2 (IIIc), His Tag (Cat. No. FGC-H5225) at 5 μg/mL (100 μL/well) can bind Biotinylated Human FGF basic, Tag Free with a linear range of 0.04-1.25 μg/mL (Routinely tested).

Synonym Name

FGF R2 (IIIc),FGFR2B,FGFR2

Background

Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Erdafitinib G-024; JNJ-493; 890E37NHMV; JNJ-42756493 Approved Balversa United States Carcinoma, Transitional Cell Janssen Biotech Inc 2019-04-12 Solid tumours; Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Hepatic Insufficiency; Lymphoma; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
Pemigatinib INCB-054828; IBI-375; INCB-54828; BH-009 Approved Incyte Corp Pemazyre, 伯坦, 达伯坦 Hong Kong Biliary Tract Neoplasms Innovent Biologics(Suzhou) Co Ltd 2020-04-17 Biliary Tract Neoplasms; Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Translocation, Genetic; Bile Duct Neoplasms; Endometrial Neoplasms Details
Regorafenib DAST; BAY-73-4506 Approved Bayer Ag Resihance, Stivarga Mainland China Gastrointestinal Stromal Tumors Bayer Pharma Ag 2012-09-27 Solid tumours; Carcinoma, Renal Cell; Rectal Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms Details
Lenvatinib Mesylate MK-7902; ER-203492-00; E-7080 Approved Eisai Co Ltd Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 Japan Endometrial Neoplasms Eisai Co Ltd 2015-02-13 Liver Diseases; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular; Lymphoma; Thyroid Neoplasms; Endometrial Neoplasms; Hepatic Insufficiency; Sarcoma; Urinary Bladder Neoplasms; Solid tumours; Adenocarcinoma of Lung; Thyroid Carcinoma, Anaplastic; Kidney Diseases; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Renal Insufficiency; Carcinoma, Renal Cell; Liver Neoplasms; Biliary Tract Neoplasms Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef Mainland China Idiopathic Pulmonary Fibrosis Boehringer Ingelheim International Gmbh 2014-10-15 Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Scleroderma, Systemic; Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pulmonary Fibrosis; Multiple Myeloma; Prostatic Neoplasms; Peritoneal Neoplasms; Hepatic Insufficiency; Genital Neoplasms, Female; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Anlotinib Dihydrochloride AL-3818 Approved Advenchen Laboratories, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 福可维 Mainland China Small Cell Lung Carcinoma Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2018-05-08 Endometrial Neoplasms; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Urologic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bone Neoplasms; Sarcoma, Alveolar Soft Part; Gallbladder Neoplasms; Medullary thyroid cancer (MTC); Thyroid Neoplasms; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Osteoma; Carcinoma, Renal Cell; Head and Neck Neoplasms; Solid tumours; Biliary Tract Neoplasms; Ovarian Neoplasms; Thoracic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Genital Diseases, Female; Leiomyosarcoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Sarcoma, Synovial; Neuroendocrine Tumors; Sarcoma; Bile Duct Diseases Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Aprutumab ixadotin BAY-1187982 Phase 1 Clinical Bayer Ag Neoplasms Details
Lucitanib AL-3810; CO-3810; S-80881 Phase 3 Clinical Advenchen Laboratories Nanjing Ltd Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Thymus Neoplasms; Genital Neoplasms, Female; Carcinoma, Small Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Aprutumab FGFR-moAb; FGFR2-TTC; BAY-1179470 Phase 1 Clinical Bayer Ag Neoplasms Details
TT-00434 TT-00434 Phase 1 Clinical Yaojie Ankang (Nanjing) Technology Co Ltd Solid tumours; Urinary Bladder Neoplasms Details
S-49076 S-49076 Phase 2 Clinical Servier Glioblastoma; Carcinoma, Non-Small-Cell Lung Details
CH-5183284 FF-284; CH-5183284; Debio-1347 Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Breast Neoplasms Details
BPI-17509 BPI-17509 Phase 1 Clinical Betta Pharmaceuticals Co Ltd Solid tumours Details
Sprifermin zFGF-5; Zfgf5; AS-902330; rhFGF-18; trFGF-18; FGF-18 Phase 2 Clinical Zymogenetics Cartilage Diseases; Knee Injuries; Osteoarthritis, Knee; Osteoarthritis Details
Alofanib RPT-835 Phase 1 Clinical Russian Pharmaceutical Technologies Llc Stomach Neoplasms Details
PRN-1371 PRN-1371 Phase 1 Clinical Principia Biopharma Inc Solid tumours; Urinary Bladder Neoplasms Details
RLY-4008 RLY-4008 Phase 1 Clinical Relay Therapeutics Inc Solid tumours; Stomach Neoplasms; Breast Neoplasms; Translocation, Genetic; Cholangiocarcinoma; Endometrial Neoplasms Details
Gunagratinib ICP-192 Phase 2 Clinical Beijing Tiancheng Pharmaceutical Technology Co Ltd Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms Details
AZD-4547 AZD-4547; ABSK-091; AZD4547; ABSK091 Phase 2 Clinical Astrazeneca Plc Solid tumours; Gastrointestinal Diseases; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Breast Neoplasms Details
HMPL-453 HMPL-453 Phase 2 Clinical Hutchison Huangpu Medicine (Shanghai) Co Ltd Biliary Tract Neoplasms; Solid tumours; Neoplasms, Mesothelial; Mesothelioma; Bile Duct Neoplasms Details
HH185 3-D185; HH-185; 3D185; 3D-185 Phase 1 Clinical Shanghai Medicilon Inc, ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Solid tumours Details
E-7090 E-7090 Phase 2 Clinical Eisai Co Ltd Biliary Tract Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Hepatic Insufficiency Details
Bemarituzumab FPA-144 Phase 3 Clinical Five Prime Therapeutics Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Adenocarcinoma; Gastrointestinal Neoplasms Details
Futibatinib TAS-120 Phase 3 Clinical Otsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd Bone Marrow Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Lymphoma; Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message